Nissar Ahmad Wani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6821107/publications.pdf

Version: 2024-02-01

331538 330025 1,678 36 21 37 citations h-index g-index papers 37 37 37 2140 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel antiâ€ŧumor mechanisms of Cannabidiol in breast cancer. Molecular Oncology, 2015, 9, 906-919.	2.1	170
2	Tumor microenvironment promotes breast cancer chemoresistance. Cancer Chemotherapy and Pharmacology, 2021, 87, 147-158.	1.1	131
3	New perspectives on folate transport in relation to alcoholismâ€induced folate malabsorption – association with epigenome stability and cancer development. FEBS Journal, 2009, 276, 2175-2191.	2.2	130
4	RAGE Mediates S100A7-Induced Breast Cancer Growth and Metastasis by Modulating the Tumor Microenvironment. Cancer Research, 2015, 75, 974-985.	0.4	112
5	Blocking the CCL2–CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Molecular Cancer Therapeutics, 2017, 16, 312-322.	1.9	101
6	C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Research, 2014, 16, R54.	2.2	93
7	Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer. Current Cancer Drug Targets, 2020, 20, 586-602.	0.8	78
8	Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Molecular Cancer, 2021, 20, 2.	7.9	76
9	The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities. Cellular Oncology (Dordrecht), 2021, 44, 1209-1229.	2.1	71
10	An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer. Future Oncology, 2021, 17, 4185-4206.	1.1	68
11	Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy. Signal Transduction and Targeted Therapy, 2021, 6, 12.	7.1	68
12	Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway. Molecular Carcinogenesis, 2016, 55, 2063-2076.	1.3	66
13	Folate status in various pathophysiological conditions. IUBMB Life, 2008, 60, 834-842.	1.5	50
14	Downâ€regulation of reduced folate carrier may result in folate malabsorption across intestinal brush border membrane during experimental alcoholism. FEBS Journal, 2007, 274, 6317-6328.	2.2	48
15	Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production. Gene Expression, 2017, 17, 129-140.	0.5	42
16	Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications. Seminars in Cancer Biology, 2022, 86, 769-783.	4. 3	36
17	miRNA-122 Protects Mice and Human Hepatocytes from Acetaminophen Toxicity by Regulating Cytochrome P450 Family 1 Subfamily A Member 2 and Family 2 Subfamily E Member 1 Expression. American Journal of Pathology, 2017, 187, 2758-2774.	1.9	35
18	Reprogramming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis. Molecular Cancer Research, 2018, 16, 256-268.	1.5	33

#	Article	IF	CITATIONS
19	Reduced levels of folate transporters (PCFT and RFC) in membrane lipid rafts result in colonic folate malabsorption in chronic alcoholism. Journal of Cellular Physiology, 2011, 226, 579-587.	2.0	29
20	Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 4584.	1.8	29
21	Expression Pattern and Prognostic Significance of Chemokines in Breast cancer: An Integrated Bioinformatics Analysis. Clinical Breast Cancer, 2022, 22, 567-578.	1.1	26
22	Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. Cancers, 2020, 12, 2730.	1.7	24
23	Regulatory mechanisms of intestinal folate uptake in a rat model of folate oversupplementation. British Journal of Nutrition, 2011, 105, 827-835.	1.2	22
24	Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma. Molecular Cancer Therapeutics, 2020, 19, 384-396.	1.9	18
25	Biochemical and Molecular Mechanisms of Folate Transport in Rat Pancreas; Interference with Ethanol Ingestion. PLoS ONE, 2011, 6, e28599.	1.1	15
26	Alcohol-associated folate disturbances result in altered methylation of folate-regulating genes. Molecular and Cellular Biochemistry, 2012, 363, 157-166.	1.4	15
27	Mechanistic insights of intestinal absorption and renal conservation of folate in chronic alcoholism. Alcohol, 2013, 47, 121-130.	0.8	14
28	Folate malabsorption is associated with down-regulation of folate transporter expression and function at colon basolateral membrane in rats. British Journal of Nutrition, 2012, 107, 800-808.	1.2	12
29	Reduced expression of folate transporters in kidney of a rat model of folate oversupplementation. Genes and Nutrition, 2014, 9, 369.	1.2	11
30	miRNAs as novel immunoregulators in cancer. Seminars in Cell and Developmental Biology, 2022, 124, 3-14.	2.3	11
31	Adaptive transport of folic acid across renal epithelia in folate-deficient rats. Journal of Physiological Sciences, 2012, 62, 461-468.	0.9	9
32	Modulation of dietary folate with age confers selective hepatocellular epigenetic imprints through DNA methylation. Journal of Nutritional Biochemistry, 2018, 53, 121-132.	1.9	9
33	Mechanism of intestinal folate transport during folate deficiency in rodent model. Indian Journal of Medical Research, 2012, 136, 758-65.	0.4	8
34	Decreased activity of folate transporters in lipid rafts resulted in reduced hepatic folate uptake in chronic alcoholism in rats. Genes and Nutrition, 2013, 8, 209-219.	1.2	7
35	Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment. Oncotarget, 2020, 11, 784-800.	0.8	4
36	Recent Advances in Head and Neck Tumor Microenvironment–Based Therapy. Advances in Experimental Medicine and Biology, 2020, 1296, 11-31.	0.8	3